Does Discontinuing Teriparatide Treatment and Replacing It with Bisphosphonate Maintain the Volume of the Bone Fusion Mass after Lumbar Posterolateral Fusion in Women with Postmenopausal Osteoporosis?

다국어 초록 (Multilingual Abstract)

Study Design: Retrospective case series.
Purpose: The purpose of this study was to determine whether discontinuing teriparatide treatment and replacing it with bisphosphonate treatment maintains the volume of the fusion mass after posterolateral fusion (PLF) in women with postmenopausal osteoporosis.
Overview of Literature: Clinical data support the efficacy of parathyroid hormone (PTH) for lumbar PLF. However, the use of PTH is limited to 2 years.
Methods: We treated 19 women diagnosed with osteoporosis and degenerative spondylolisthesis with teriparatide (20 μg daily subcutaneously). All patients underwent one-level instrumented PLF. Teriparatide was used during 2 months prior to surgery and more than 8 months after surgery. After discontinuing teriparatide treatment, all patients used bisphosphonate (17.5 mg risedronate weekly, oral administration). Area of the fusion mass across the transverse processes at one segment was determined on an anteroposterior radiograph at 1, 2, and 3 years after surgery.
Results: We followed 19 patients for 3 years. The average duration of teriparatide treatment was 11.5 months. The bone union rate was 95%. The average area of the bone fusion mass was not significantly different between the right and left sides at 1, 2, or 3 years after surgery (p >0.05).
Conclusions: This study showed that replacing teriparatide treatment with bisphosphonate maintained the bone fusion mass volume after PLF in women with postmenopausal osteoporosis.

참고문헌 (Reference)

1 Yamamoto T, "The safety and effectiveness profile of daily teriparatide in a prospective observational study in Japanese patients with osteoporosis at high risk for fracture: interim report" 32 : 699-708, 2014

2 Kurland ES, "The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]" 15 : 992-997, 2004

3 Rubery PT, "Teriparatide may accelerate healing in delayed unions of type III odontoid fractures: a report of 3 cases" 23 : 151-155, 2010

4 Ohtori S, "Teriparatide accelerates lumbar posterolateral fusion in women with postmenopausal osteoporosis: prospective study" 37 : E1464-E1468, 2012

5 O’Loughlin PF, "Parathyroid hormone (1-34) augments spinal fusion, fusion mass volume, and fusion mass quality in a rabbit spinal fusion model" 34 : 121-130, 2009

6 Bae HW, "Nationwide trends in the surgical management of lumbar spinal stenosis" 38 : 916-926, 2013

7 Seiji Ohtori, "More than 6 Months of Teriparatide Treatment Was More Effective for Bone Union than Shorter Treatment Following Lumbar Posterolateral Fusion Surgery" 대한척추외과학회 9 (9): 573-580, 2015

8 Abe Y, "Enhancement of graft bone healing by intermittent administration of human parathyroid hormone (1-34) in a rat spinal arthrodesis model" 41 : 775-785, 2007

9 Rittmaster RS, "Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate" 85 : 2129-2134, 2000

10 Dempster DW, "Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study" 16 : 1846-1853, 2001

11 Bransford R, "Effect of zoledronic acid in an L6-L7 rabbit spine fusion model" 16 : 557-562, 2007

12 Lehman RA Jr, "Effect of teriparatide [rhPTH(1,34)] and calcitonin on intertransverse process fusion in a rabbit model" 35 : 146-152, 2010

13 Neer RM, "Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis" 344 : 1434-1441, 2001

14 Nagahama K, "Does alendronate disturb the healing process of posterior lumbar interbody fusion? A prospective randomized trial" 14 : 500-507, 2011

15 Soen S, "Diagnostic criteria for primary osteoporosis: year 2012 revision" 31 : 247-257, 2013

16 Ohtori S, "Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective" 38 : E487-E492, 2013

17 McGovern SC, "Can bone morphogenetic protein binding peptide increase efficiency of bone formation?" 35 : 1655-1659, 2010

18 Muschitz C, "Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density" 28 : 196-205, 2013

19 Miyazaki M, "An update on bone substitutes for spinal fusion" 18 : 783-799, 2009

20 Huang RC, "Alendronate inhibits spine fusion in a rat model" 30 : 2516-2522, 2005